The medical technology company attributes the increase to European sales of its new product, orthoPACE, for orthopedics, sports medicine and trauma indications, which was launched in July 2010.
The company’s Q1 net loss for the first quarter of 2011 was $2.2 million, compared with a net loss of $3 million for the first quarter of 2010.
Read the company news release about SANUWAVE Health’s first quarter financial results.
Related Articles on Financial Reports:
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales
BioMimetic Therapeutics Posts $8M Net Loss in Q1
